IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

ANTONARELLI, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.551
AS - Asia 1.266
NA - Nord America 879
SA - Sud America 107
AF - Africa 21
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.837
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 1.027
US - Stati Uniti d'America 839
SG - Singapore 375
CN - Cina 368
IT - Italia 172
HK - Hong Kong 143
BD - Bangladesh 116
SE - Svezia 95
VN - Vietnam 86
BR - Brasile 76
RU - Federazione Russa 75
IN - India 74
FR - Francia 58
NL - Olanda 31
ID - Indonesia 28
FI - Finlandia 27
GB - Regno Unito 19
CA - Canada 16
IE - Irlanda 16
TR - Turchia 13
JP - Giappone 12
AR - Argentina 11
PH - Filippine 11
PL - Polonia 10
MX - Messico 9
AU - Australia 8
KR - Corea 8
CI - Costa d'Avorio 7
AT - Austria 6
TW - Taiwan 6
ZA - Sudafrica 6
CO - Colombia 5
JM - Giamaica 5
SA - Arabia Saudita 5
EC - Ecuador 4
NZ - Nuova Zelanda 4
PK - Pakistan 4
BE - Belgio 3
CL - Cile 3
IQ - Iraq 3
UZ - Uzbekistan 3
BO - Bolivia 2
CR - Costa Rica 2
EG - Egitto 2
ES - Italia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
PA - Panama 2
PE - Perù 2
RO - Romania 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UA - Ucraina 2
VE - Venezuela 2
AL - Albania 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
LB - Libano 1
MD - Moldavia 1
OM - Oman 1
PY - Paraguay 1
SC - Seychelles 1
SR - Suriname 1
SV - El Salvador 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.837
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 992
Singapore 176
Ashburn 170
Hong Kong 130
San Jose 86
Hefei 61
Santa Clara 58
Los Angeles 56
Beijing 54
Council Bluffs 48
New York 38
Dallas 36
Milan 34
Bengaluru 30
Boardman 30
Hanoi 28
Ho Chi Minh City 25
Lauterbourg 23
Shanghai 23
Chandler 20
Helsinki 19
Moscow 19
Buffalo 18
Hyderabad 18
Jakarta 17
Dublin 16
Naples 13
Guangzhou 11
Munich 11
Cangzhou 10
Chennai 10
Istanbul 9
Tokyo 9
Boston 8
Rome 8
São Paulo 8
Abidjan 7
Oklahoma City 7
Florence 6
Nuremberg 6
Rho 6
Warsaw 6
Wuhan 6
Bari 5
Bologna 5
Düsseldorf 5
Lappeenranta 5
Orem 5
Paris 5
Quanzhou 5
Seattle 5
Sydney 5
Atlanta 4
Bến Tre 4
Charlotte 4
Chicago 4
Haiphong 4
Huizhou 4
Miano 4
Montreal 4
Ranchi 4
Roubaix 4
Seoul 4
Tianjin 4
Baghdad 3
Belmont 3
Brasília 3
Brooklyn 3
Da Nang 3
Dammam 3
Denver 3
Dhaka 3
Fuzhou 3
Gainesville 3
Islamabad 3
Johannesburg 3
Manila 3
Nanjing 3
Phoenix 3
Portsmouth 3
Princeton 3
Redmond 3
Reggio Emilia 3
Rio de Janeiro 3
San Diego 3
Santiago 3
Taipei 3
Tashkent 3
The Dalles 3
Toronto 3
Turku 3
Vienna 3
Weifang 3
Wroclaw 3
Bandung 2
Barranquilla 2
Bishkek 2
Bollate 2
Brescia 2
Brisbane 2
Totale 2.561
Salva come PNG Salva come JPEG
Nome #
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 325
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 251
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 244
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population 235
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group 204
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 202
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers 197
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 193
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies 183
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer 168
Therapeutic Cancer Vaccines Revamping: Technology Advancements and Pitfalls 166
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 157
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review 148
COVID-19 related risk in patients enrolled in early-phase clinical trials 146
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 146
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? 141
Harmonizing PD-L1 testing in metastatic triple negative breast cancer 139
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development 137
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? 136
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 119
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation 93
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 90
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility 64
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer 13
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients 13
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study 8
From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials 7
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards 7
Redefining clinical trial strategic design to support drug approval in medical oncology 4
Pembrolizumab and oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1) 3
Targeting brain metastases in breast cancer 3
Emerging treatment landscape of non-muscle invasive bladder cancer 2
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies 1
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting 1
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study 1
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment 1
Totale 3.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.805
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.805
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202250 0 0 1 4 9 4 9 11 5 3 2 2
2022/2023111 8 12 19 10 10 22 6 1 6 2 9 6
2023/2024954 15 17 29 33 70 51 155 120 58 121 143 142
2024/2025973 116 129 123 105 55 26 16 57 44 77 75 150
2025/20261.860 204 170 166 155 108 60 246 97 152 108 259 135
Totale 3.948